Saul Shiffman1,2, Deena R Battista1, Judith P Kelly3, Mary K Malone4, Rachel B Weinstein5, David W Kaufman3. 1. Pinney Associates, Pittsburgh, PA, USA. 2. Departments of Psychology, Psychiatry, Pharmaceutical Sciences, and Clinical Translational Research, University of Pittsburgh, Pittsburgh, PA, USA. 3. Slone Epidemiology Center at Boston University, Boston, MA, USA. 4. Appleseed Consumer Insight, Arlington, MA, USA. 5. Janssen Research & Development, LLC, Titusville, NJ, USA.
Abstract
AIMS: To estimate prevalence of excess intake of paracetamol and investigate seasonal variations therein. METHODS: Between 2011 and 2016, 14 481 US adults who used paracetamol in the preceding 30 days were sampled from national online panels and completed a detailed online daily diary of paracetamol medication use for 7 days. Respondents were not told that the study concerned paracetamol. Cold/flu season (CFS), identified using Google Trends data, was contrasted to off-season in symptoms, use of paracetamol medications, and consumption exceeding 4 g (the recommended daily maximum). RESULTS: Overall, 6.3% [95% confidence interval: 5.9-6.7%] of users exceeded 4 g on at least one day; 3.7% [3.5-3.8%] of usage days exceeded 4 g. Cold/flu symptoms were more likely to be experienced and treated with paracetamol in CFS than off-season. Paracetamol users were more likely to exceed 4 g during CFS (6.5% vs. 5.3%; odds ratio = 1.24, 1.04-1.48); days exceeding 4 g also increased (3.9% vs. 2.8%; odds ratio = 1.37, 1.11-1.69). This was not due to differences in characteristics of individuals using paracetamol in CFS, but primarily to increased use of over-the-counter combination medications designed to treat upper respiratory cold/flu symptoms (33.2% of usage days in CFS vs. 24.8% in off-season; odds ratio = 1.58, 1.46-1.72). When such medications were omitted, there was no statistically significant seasonal variation in exceeding 4 g. CONCLUSIONS: Paracetamol use and over-dosing increases in CFS, primarily due to increased use of over-the-counter combinations treating upper respiratory cold/flu symptoms. Pharmacists should warn users to follow labelled dosing directions, especially during CFS.
AIMS: To estimate prevalence of excess intake of paracetamol and investigate seasonal variations therein. METHODS: Between 2011 and 2016, 14 481 US adults who used paracetamol in the preceding 30 days were sampled from national online panels and completed a detailed online daily diary of paracetamol medication use for 7 days. Respondents were not told that the study concerned paracetamol. Cold/flu season (CFS), identified using Google Trends data, was contrasted to off-season in symptoms, use of paracetamol medications, and consumption exceeding 4 g (the recommended daily maximum). RESULTS: Overall, 6.3% [95% confidence interval: 5.9-6.7%] of users exceeded 4 g on at least one day; 3.7% [3.5-3.8%] of usage days exceeded 4 g. Cold/flu symptoms were more likely to be experienced and treated with paracetamol in CFS than off-season. Paracetamol users were more likely to exceed 4 g during CFS (6.5% vs. 5.3%; odds ratio = 1.24, 1.04-1.48); days exceeding 4 g also increased (3.9% vs. 2.8%; odds ratio = 1.37, 1.11-1.69). This was not due to differences in characteristics of individuals using paracetamol in CFS, but primarily to increased use of over-the-counter combination medications designed to treat upper respiratory cold/flu symptoms (33.2% of usage days in CFS vs. 24.8% in off-season; odds ratio = 1.58, 1.46-1.72). When such medications were omitted, there was no statistically significant seasonal variation in exceeding 4 g. CONCLUSIONS:Paracetamol use and over-dosing increases in CFS, primarily due to increased use of over-the-counter combinations treating upper respiratory cold/flu symptoms. Pharmacists should warn users to follow labelled dosing directions, especially during CFS.
Authors: Timothy E Albertson; Victor M Walker; Marilyn R Stebbins; Elisa W Ashton; Kelly P Owen; Mark E Sutter Journal: Ann Pharmacother Date: 2010-06-15 Impact factor: 3.154
Authors: Saul Shiffman; Deena R Battista; Judith P Kelly; Mary K Malone; Rachel B Weinstein; David W Kaufman Journal: Br J Clin Pharmacol Date: 2018-03-25 Impact factor: 4.335
Authors: David W Kaufman; Judith P Kelly; Deena R Battista; Mary Kathryn Malone; Rachel B Weinstein; Saul Shiffman Journal: Am J Prev Med Date: 2015-12-11 Impact factor: 5.043
Authors: Jeremy Ginsberg; Matthew H Mohebbi; Rajan S Patel; Lynnette Brammer; Mark S Smolinski; Larry Brilliant Journal: Nature Date: 2009-02-19 Impact factor: 49.962
Authors: Sungjin Cho; Chang Hwan Sohn; Min Woo Jo; Soo-Yong Shin; Jae Ho Lee; Seoung Mok Ryoo; Won Young Kim; Dong-Woo Seo Journal: PLoS One Date: 2013-12-05 Impact factor: 3.240
Authors: Sudhakar V Nuti; Brian Wayda; Isuru Ranasinghe; Sisi Wang; Rachel P Dreyer; Serene I Chen; Karthik Murugiah Journal: PLoS One Date: 2014-10-22 Impact factor: 3.240
Authors: David W Kaufman; Judith P Kelly; Deena R Battista; Mary K Malone; Rachel B Weinstein; Saul Shiffman Journal: Br J Clin Pharmacol Date: 2019-03-18 Impact factor: 4.335
Authors: Saul Shiffman; Deena R Battista; Judith P Kelly; Mary K Malone; Rachel B Weinstein; David W Kaufman Journal: Br J Clin Pharmacol Date: 2018-03-25 Impact factor: 4.335
Authors: Dilara Bayram; Volkan Aydin; Abdullah Sanli; Mustafa Naci Abanoz; Busra Sibic; Sedat Pala; Omer Atac; Ahmet Akici Journal: Prim Health Care Res Dev Date: 2021-12-02 Impact factor: 1.458